Surgery Websites
LiverSource »  Faculty »  Hepatology »  Francis Y.K. Yao, M.D.
Francis Y.K. Yao, M.D.

Francis Y.K. Yao, M.D.

  • Professor of Clinical Medicine and Surgery,
  • Departments of Medicine and Surgery
  • Medical Director, Liver Transplant Service
  • Director for Community Liaison, Liver Transplant Service

Contact Information

Academic Office
Division of Gastroenterology
513 Parnassus Avenue, Room S-357
San Francisco, CA 94143-0358
Phone: (415) 514-0332
Fax: 415-476-0659
[email protected]
Open Popup

1979-1980 University of San Francisco, Chemistry Major

1980-1983 University of California, Berkeley B.S. Chemistry with High Honors

1983-1987 Albert Einstein College of Medicine. M.D. Medicine

  • 1987-1988 Stanford University Hospital, Intern, Internal Medicine
  • 1988-1990 Stanford University Hospital, Resident, Internal Medicine
  • 1990-1993 Stanford University Hospital, Fellow, Gastroenterology
  • 1995 American Board of Internal Medicine - ABIM 147033 (Re-certification 2008)
  • 1997 American Board of Gastroenterology - ABIM 147033
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Liver Transplant Program
  • UCSF Liver Center
  • Hepatitis in Asians
  • Liver Injury and Repair
  • Liver transplantation outcomes including expanded criteria liver transplants
  • Loco-regional therapy for hepatocellular carcinoma

Dr. Francis Yao is a gastroenterologist and medical director of the Liver Transplant Program at UCSF Medical Center. Dr. Yao is a professor of medicine in the UCSF School of Medicine. He also is director of UCSF's Liver Transplant Outreach and Community Liaison Program. In his research, he is interested in liver cancer treatment, particularly related to liver transplants, and has contributed to important publications in this area. His other research interests include hepatitis B infection and outcomes for liver transplantation.

Data provided by UCSF Profiles, powered by CTSI
  1. Norman JS, Li PJ, Kotwani P, Shui AM, Yao F, Mehta N. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol. 2023 Sep 07. View in PubMed
  2. Natarajan B, Tabrizian P, Hoteit M, Frenette C, Parikh N, Ghaziani T, Dhanasekaran R, Guy J, Shui A, Florman S, Yao FY, Mehta N. Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium. Am J Transplant. 2023 11; 23(11):1771-1780. View in PubMed
  3. Mehta N, Kelley RK, Yao FY. Refining the approach to down-staging for hepatocellular carcinoma prior to liver transplantation: Patient selection, local-regional treatments, and systemic therapies. Hepatology. 2023 May 16. View in PubMed
  4. Mehta N, Kotwani P, Norman J, Shui A, Li PJ, Saxena V, Chan W, Yao FY. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study. Liver Transpl. 2023 10 01; 29(10):1041-1049. View in PubMed
  5. Huang AC, Dodge JL, Yao FY, Mehta N. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers. Clin Gastroenterol Hepatol. 2023 06; 21(6):1581-1589. View in PubMed
  6. View All Publications


Site Directory